Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSAEnriqueta Felip, S.-H. Lee, N. Girard et al.|Annals of Oncology|2024Cited by 81
59P Datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC): Nonsquamous (NSQ) histology in the phase III TROPION-Lung01 trialN. Girard, M-J. Ahn, Isamu Okamoto et al.|ESMO Open|2024Cited by 5
133TiP: A randomized phase III study of ivonescimab versus pembrolizumab as first-line treatment of metastatic non-small cell lung cancer as first-line treatment of metastatic non-small cell lung cancer with high tumor PD-L1 expression: HARMONi-7Antonio Passaro, Antonio Calles, N. Girard et al.|Journal of Thoracic Oncology|2025Cited by 1